Skip to main content

Incyte United States revenue

  • INCY · Nasdaq
  • Biotechnology
  • S&P 500
$120.97−0.60%Close 13 Nov 2026 · Market value $24.66B

United States revenue at Incyte came to $1.4B for the quarter to 30 Sep 2026, up 13.8% from a year earlier.

As Incyte reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$828.2MMar 2024$989.0MJun 2024$1.1BSep 2024$1.1BDec 2024$981.6MMar 2025$1.1BJun 2025$1.3BSep 2025$1.4BDec 2025$1.2BMar 2026$1.6BJun 2026$1.4BSep 2026
Incyte United States revenue, every reported period
Period endingUnited States revenueChange on a yearFiled
30 Sep 2026$1.4Bup 13.8%29 Oct 2026
30 Jun 2026$1.6Bup 37.8%28 Jul 2026
31 Mar 2026$1.2Bup 19.3%28 Apr 2026
31 Dec 2025$1.4Bup 31.0%10 Feb 2026
30 Sep 2025$1.3Bup 17.9%28 Oct 2025
30 Jun 2025$1.1Bup 14.5%29 Jul 2025
31 Mar 2025$981.6Mup 18.5%29 Apr 2025
31 Dec 2024$1.1B—10 Feb 2025
30 Sep 2024$1.1B—29 Oct 2024
30 Jun 2024$989.0M—30 Jul 2024
31 Mar 2024$828.2M—30 Apr 2024

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Incyte: Customer A (change on a year) · Customer B (change on a year) · Customer C (change on a year) · JAKAFI revenue · OPZELURA revenue · Product royalty revenues · JAKAVI revenue · NIKTIMVO revenue · ZYNYZ revenue · MINJUVI/MONJUVI revenue · Milestone and contract revenues · OLUMIANT revenue · ICLUSIG revenue · PEMAZYRE revenue · TABRECTA revenue · Europe revenue · financial statements

Every KPI and segment of INCY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.